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Poster Session I 91screened 12 OS and EWS cell lines for HER2 expression by FACS
analysis and analyzed the ability of HER2-T cells to 1) proliferate,
2) produce immunostimulatory cytokines, and 3) kill HER21 tu-
mor cells in cytoxicity assays upon exposure to HER21 OS and
EWS cell lines. The in vivo function was tested in amurine intraper-
itoneal xenograft model, which allows for serial imaging by biolu-
minescence with representative OS (LM7) and EWS (TC71) cell
lines. Imaging results were confirmed by pathological examination.
Results: 10 of 12 cell lines were HER21 by FACS analysis. HER2-
T cells recognized and killed all HER21OS and EWS cell lines in
cytotoxicity assays, whereas HER2-negative tumor cells were not
killed. Coculture ofHER2-T cells withHER21 tumor cell lines re-
sulted in T-cell proliferation, and secretion of IFN-g and IL-2 in
a HER2-dependent manner. In vivo, HER2-T cells eradicated es-
tablished intraperitoneal xenografts in 80% of animals harboring
LM7 and 70% of those harboring TC71 tumors, resulting in
long-term tumor free survival of treated animals. In contrast, deliv-
ery of non-transduced T cells did not change the tumor growth pat-
tern.Conclusions:This study shows that HER2 is a target antigen
for adoptive immunotherapy of OS and EWS. HER2-redirected T
cells not only recognized and killedHER21 tumor cells ex vivo, but
also eradicated experimental xenografts in vivo. Hence, adoptive
transfer of HER2-redirected T cells may represent a promising im-
munotherapeutic approach for OS and EWS.246
OPTIMIZING IMMUNOTHERAPY IMMEDIATELY AFTER HEMATOPOIETIC
STEM CELL TRANSPLANTATION (HSCT) TO EFFECTIVELY TREAT ESTAB-
LISHED NEUROBLASTOMA
Jing, W., Yan, X., Orentas, R.J., Johnson, B.D. Medical College of Wis-
consin, Milwaukee, WI.
Based on our previous success at inducing ‘‘protective’’ immunity
to neuroblastoma immediately after syngeneic HSCT using a com-
bination of adoptive immunotherapy and tumor vaccination, we hy-
pothesized that a similar immunotherapeutic approach would be
able to effectively treat mice with established tumors. Mice bearing
established AGN2a (neuroblastoma) tumors were given lethal total
body irradiation followed by HSCT consisting of bone marrow
supplemented with 6  106 T cells. On days 2, 7, and 14 after
HSCT, mice were vaccinated with irradiated AGN2a cells that
had been genetically modified to express CD54, CD80, CD86,
and CD137L. Bioluminescent imaging and caliper measurements
were used to monitor tumor growth. Our best results – delayed tu-
mor growth in all mice and 70% tumor-free survival – were seen
when mice were given HSCT, T cells derived from tumor-vacci-
nated syngeneic donors (pre-sensitized T cells), and vaccination.
Vaccination was an important component of the immunotherapy
in these mice, as only 36% of mice given pre-sensitized T cells
only (no vaccine) survived long-term. Several of the mice given
pre-sensitized T cells without vaccination had late tumor recur-
rences, which were not observed in vaccinated mice. This may re-
flect the requirement of a vaccine-based approach for the
induction or maintenance of long-term immune memory. Mice
givenHSCT, adoptive T cell transfer from naı¨ve mice, and vaccina-
tion also showed delayed tumor growth, but tumor-free survival was
lower (33%). Overall survival correlated with the frequency of IFN-
g-producing, tumor-reactive CD81 cells in lymphoid tissues of
treated mice. Moreover, we demonstrate that mice with regressing
tumors had higher frequencies of tumor-reactive T cells in their
lymphoid tissues thanmice with progressing tumors.When specific
immune cell subsets were depleted from the adoptively transferred
T cells two important observations were made. First, CD41 T cell
depletion was found to initially benefit tumor-bearing hosts, but the
generation of anti-tumor T cell memory was inhibited. Second,
more specific depletion of CD4 1 251 cells from the adoptively
transferred T cells can result in better tumor immunity without de-
creasing anti-tumorT cell memory. In summary, our results suggest
that a multi-faceted immunotherapeutic strategy including HSCT,
T cell adoptive transfer and early post-transplant tumor vaccination
can effectively treat mice with established neuroblastoma.247
HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL SUP-
PORT VERSUS STANDARD-DOSE CHEMOTHERAPY FOR HIGH-RISK
BREAST CANCER: META-ANALYSIS OF INDIVIDUAL PATIENT DATA
FROM 15 RANDOMIZED ADJUVANT TRIALS
Ueno, N.T.1, Berry, D.A.1, Johnson, M.M.1, Lei, X.1, Lopez, V.T.1,
Caputo, J.A.1, Bregni, M.2, Demirer, T.2. 1The University of Texas
MD Anderson Cancer Center, Houston, TX; 2European Group for Blood
and Marrow Transplantation Meta-Analysis Group.
Background: The role of adjuvant high-dose chemotherapy
(HDC) with autologous hematopoietic stem-cell transplantation
for primary breast cancer at high risk of recurrence (at least 4 in-
volved axillary lymph nodes) remains ill-defined. Data from individ-
ual trials have limited power to show overall or subgroup benefit for
this indication. Methods: Individual patient data from 15 known
randomized trials (HDC vs standard-dose chemotherapy [SDC])
were merged into a single database. Disease-free survival (DFS)
was defined as time from surgery to recurrence or death; breast can-
cer-specific survival (BCSS) was time from surgery to death from
breast cancer or treatment-related toxicity; and overall survival
(OS) was time from surgery to death. Cox proportional hazards re-
gression was used to compare the effect of HDC vs SDC on DFS,
BCSS, and OS adjusted for age, trial, hormone receptor (HmR) sta-
tus (positive if either estrogen or progesterone receptor was posi-
tive), and menopausal (MP) status. Subgroup analyses were by
age, HmR and MP status. Results:Median follow-up for 6,210 pa-
tients (3,118HDC, 3,092 SDC) was 6 years (range, 0–15.3); median
patient age was 46 years (range, 20–67). HmR status was positive in
46.8% of patients, negative in 23.7%, and unknown in 29.5%;
68.9% were premenopausal, 29.4% were postmenopausal, and
1.7% was unknown.
After adjusting for age, trial andMP, HDCwas found to prolong
DFS (hazard ratio [HR] 0.87; 95% confidence interval [CI] 0.81–
0.94; P 5 0.0002) but not BCSS (HR 0.93; 95% CI 0.85–1.02; P
5 0.12) or OS (HR 0.95; 95%CI 0.87–1.03; P5 0.18). After adjust-
ing for HmR in the subset for which that information was available,
HDCwas found to prolong DFS (HR 0.83; 95%CI 0.77–0.90; P\
0.0001) and had modest but significant benefits on BCSS (HR 0.88;
CI 0.79–0.97; P5 0.014) andOS (HR 0.89; 95%CI 0.81–0.98; P5
0.016) compared to SDC. For BCSS and OS, none of age, MP or
HmR had a significant interaction with treatment, yet there was
a significant age by treatment interaction for DFS, in which HDC
was better for younger rather than older patients. Conclusions:
HDC as used in these 15 randomized studies prolongs DFS in ad-
juvant breast cancer. HDC has at most a modest benefit on BCSS
and OS compared to SDC. Whether HDC has benefit in the con-
text of contemporary taxane-based regimens and targeted therapies
is unknown and may be resolved by future clinical trials.248
KIR RECEPTOR-LIGAND INCOMPATIBILITY PREDICTS SUSCEPTIBILITY
OF OSTEOSARCOMA TO NK-MEDIATED LYSIS
Delgado, D.1, Hardin, H.2, Webster, D.2, DeSantes, K.1, Shaaban, A.2.
1University of Wisconsin School of Medicine & Public Health, Madison,
WI; 2University of Wisconsin School of Medicine & Public Health, Mad-
ison, WI.
Long-term survival for pediatric patients with high-risk solid tu-
mors remains poor despite multi-modality treatment, and new ap-
proaches are needed. Although the success of KIR (Killer
Immunoglobulin-Like Receptor) incompatible, haploidentical
stem cell transplantation has been suggested in hematological ma-
lignancies in adults and children, it has not been thoroughly exam-
ined for pediatric solid tumors. In this study, we evaluated the
potential for KIR-incompatible lysis of osteosarcoma cells, in vitro.
We hypothesized that the killing of osteosarcoma cell targets could
be predicted by the degree of KIR receptor/ligand mismatch. To
test this hypothesis, healthy donor NK cells were isolated and
KIR phenotype determined by flow cytometry. Consistent with pre-
vious studies, donorNK cells exhibited a high prevalence of all three
